Harvard University researchers are taking aim at COVID-19 and other diseases with a faster, simpler, cheaper technology for generating specialized antibodies.
Harvard University researchers are taking aim at COVID-19 and other diseases with a faster, simpler, cheaper technology for generating specialized antibodies.